

Environment, Health, Safety and Sustainability

Building a Healthier and More Environmentally Sustainable Future

Environment, Health, Safety and Sustainability (EHS&S) refers to the practices to protect the health and safety of employees and the public as well as the environment. Strong EHS&S management requires the implementation of systems and processes to assess and control the risks of environmental impacts and health and safety hazards. Besides assuring compliance with applicable legislation, EHS&S management systems drive continuous improvement and learning.

Equally important, the rapidly growing rate of resource consumption throughout the world is unsustainable. The pharmaceutical industry recognises that reversing the use of natural resources, the degradation of ecosystems and the disruption of the environmental systems that support human life, are critical for the benefit of current and future generations. Therefore, we believe that an increased focus on environmental sustainability is key for the future health of our planet.

EFPIA member companies strive to invent, produce, and distribute new medicines and vaccines in a safe and environmentally responsible manner. Furthermore, we are actively providing a safe and healthy workplace while reducing the environmental impact in our operations and those of our supply partners around the world. A risk management approach is employed to create transformational health innovations, while protecting our employees and employing practical aspects of environmental sustainability.

Building a Healthier and More Environmentally Sustainable Future

The pharmaceutical industry is committed to building a healthier and more environmentally sustainable future. We do this by driving an agile, innovative, evidence-based sustainability strategy to enable the pharmaceutical industry to embrace evolutions in science, technology & society and to integrate sustainability across our entire value chain to deliver quality-based, healthy, and green outcomes while positively impacting on the lives of patients.

EFPIA welcomes and embraces the Commission's focus on the Green Agenda and a more sustainable Europe and looks forward to engaging constructively on the roll-out of their policy priorities.

Our members are dedicated to making a positive impact on the lives of patients whilst operating in a sustainable manner. As we have a responsibility toward the health of the population, we are moving forward in making a beneficial impact by actively addressing climate change and the transition to a circular economy with changes throughout the value chain, as we continue to innovate.



What are we doing?

Environmental sustainability is a key value driver to accelerate delivery, improve efficiency and sustain transformational health innovation. Our industry encourages appropriate use of a risk-based approach to environmental challenges and undertakes initiatives to promote greater environmental responsibility.


The European pharmaceutical industry is committed to continue playing an active role in addressing concerns around risks associated with Pharmaceuticals in the Environment (PiE). Minimising the impact of medicines on the environment while safeguarding access to effective treatments for patients is a critical issue across all sectors of healthcare.

At EFPIA, we believe that a collaborative approach allows us to increase our mutual knowledge and understanding on how to proactively address any potential risks imposed by the presence of PiE. To this end, EFPIA, AESGP and Medicines for Europe have developed the Eco-Pharmaco-Stewardship (EPS) framework that applies the widely accepted principles of product stewardship and is implemented across the industry and with broader stakeholders in the healthcare and environmental sector.



The pharmaceutical sector is one of the most regulated in Europe and the world. Accordingly, the pre-approval of manufacturing plants, clinical trials and marketing authorisations should be given consideration when implementing and interpreting some elements of EU Chemicals legislation. The long development timelines and highly regulated nature of this industry are fundamental aspects of the ability to react to changes in legislation (e.g. restriction of chemicals). Chemical processes comprise a significant portion of a medicine's environmental footprint, and responsible use of chemicals is a key environmental stewardship priority for the sector.

Our member companies lead projects and initiatives to minimise the impact of their manufacturing process, including reducing the generation of hazardous waste, and using greener solvents. Due to the global operation of our companies and increasing number of countries with



emerging chemical legislation, it is crucial that collaborations take place between industry and regulators globally. EFPIA supports the need to develop a sustainable chemicals strategy and to promote research & development for the transformation of the chemical industry and the creation of green and sustainable manufacturing.

Direct or indirect human activities have altered the composition of the global atmosphere and increased carbon dioxide emissions, driving up temperatures. This has led to what we often observe as more extreme weather conditions and is referred to as climate change.

The pharmaceutical industry contributes to a healthy environment while demonstrating leadership in mitigating climate change. Our activities support the ambition the European Commission expressed through their European Climate policies. EFPIA member companies are committed to:

- Establishing climate change policies and strategies based on materiality and impact for individual companies and addressing their entire value chains.
- Pursuing science based CO₂e reduction targets.
- Contributing to reduced energy consumption and increased energy efficiency and seeking opportunities to use energy from renewable sources throughout the value chain.
- Annually and publicly disclosing CO₂ performance calculated according to recognized methodologies such as e.g., the World Resources Institute Greenhouse Gas Protocol.

The Pharmaceutical Industry is supportive of a circular approach to its operations and products and is aligned with the European Commission's Circular Economy Action Plan.

We will achieve the goals of the Circular Economy Action Plan concurrent with our aspiration to safeguard the future supply of pharmaceuticals for patients and improve human health.

The pharmaceutical industry's approach to circularity builds on our long experience in environmental sustainability, while recognising the constraints (e.g., speed of transition), from operating in a highly regulated industry. Circularity and regulation of pharmaceuticals should be carefully balanced. The innovation to enable circularity will drive new opportunities for growth, promote greater resource efficiency, create a more competitive economy and reduce pollutants.

Implementation of a circular economy is fundamental to help limit the global temperature increase to less than or equal to 1.5C, and we welcome the opportunity to be part of the solution by working collaboratively with the EU in shaping the legislative framework and within our organizations to mitigate our impacts.

EFPIA

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the biopharmaceutical industry operating in Europe. Through its direct membership of 37 national associations, 38 leading pharmaceutical companies and a growing number of small and medium-sized enterprises (SMEs), EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.